Assetmark Inc. Purchases 82,275 Shares of Jazz Pharmaceuticals PLC $JAZZ

Assetmark Inc. grew its position in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 9,759.8% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 83,118 shares of the specialty pharmaceutical company’s stock after acquiring an additional 82,275 shares during the period. Assetmark Inc. owned about 0.14% of Jazz Pharmaceuticals worth $8,820,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Teacher Retirement System of Texas lifted its stake in shares of Jazz Pharmaceuticals by 0.6% during the 2nd quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock worth $1,651,000 after buying an additional 90 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Jazz Pharmaceuticals by 0.6% during the 1st quarter. Louisiana State Employees Retirement System now owns 16,900 shares of the specialty pharmaceutical company’s stock worth $2,098,000 after buying an additional 100 shares during the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych lifted its stake in shares of Jazz Pharmaceuticals by 8.7% during the 2nd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock worth $133,000 after buying an additional 100 shares during the last quarter. Sound View Wealth Advisors Group LLC lifted its stake in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company’s stock worth $1,046,000 after buying an additional 110 shares during the last quarter. Finally, Securian Asset Management Inc. lifted its stake in shares of Jazz Pharmaceuticals by 2.7% during the 2nd quarter. Securian Asset Management Inc. now owns 4,694 shares of the specialty pharmaceutical company’s stock worth $498,000 after buying an additional 124 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

Wall Street Analyst Weigh In

JAZZ has been the subject of a number of research reports. Morgan Stanley set a $183.00 target price on shares of Jazz Pharmaceuticals in a research note on Friday, October 24th. Zacks Research upgraded shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. JPMorgan Chase & Co. dropped their price objective on shares of Jazz Pharmaceuticals from $204.00 to $199.00 and set an “overweight” rating for the company in a research note on Monday, October 27th. Truist Financial lifted their price objective on shares of Jazz Pharmaceuticals from $200.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 28th. Finally, The Goldman Sachs Group lifted their price objective on shares of Jazz Pharmaceuticals from $162.00 to $185.00 and gave the stock a “buy” rating in a research note on Friday, August 29th. Fourteen research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Jazz Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $179.33.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $137.64 on Friday. The company has a 50-day simple moving average of $132.19 and a two-hundred day simple moving average of $118.24. The stock has a market capitalization of $8.35 billion, a price-to-earnings ratio of -20.45, a price-to-earnings-growth ratio of 8.49 and a beta of 0.28. The company has a quick ratio of 1.37, a current ratio of 1.62 and a debt-to-equity ratio of 1.17. Jazz Pharmaceuticals PLC has a twelve month low of $95.49 and a twelve month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) EPS for the quarter, missing the consensus estimate of ($5.61) by ($2.64). The firm had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. Jazz Pharmaceuticals’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $5.30 earnings per share. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Insider Activity at Jazz Pharmaceuticals

In other news, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 2nd. The shares were sold at an average price of $128.62, for a total value of $771,720.00. Following the completion of the transaction, the director directly owned 429,973 shares in the company, valued at approximately $55,303,127.26. The trade was a 1.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In the last ninety days, insiders have sold 11,500 shares of company stock valued at $1,525,280. 4.30% of the stock is currently owned by insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.